Physician profile
Derek Keith Johnson
NPI 1386603850
$1,582.57
in general payments reported to CMS, 2019-2025
27 companies · $104 in 2025
The $104 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $214 · 2021: $572 · 2022: $216 · 2023: $89.62 · 2024: $84.94 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $211.41 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $199.63 | 2019-2021 | |
| Alk-Abello, INC | $145.26 | 2019 | |
| Glaxosmithkline, LLC. | $133.48 | 2019-2023 | Bexsero, Pediarix |
| Tris Pharma INC | $109.38 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.08 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $66.48 | 2019-2024 | Vaxelis, Gardasil, Rotateq |
| Sobi, INC | $64.02 | 2020-2022 | |
| Cranial Technologies, INC | $58.77 | 2019-2025 | Doc Band |
| Neos Therapeutics, LP | $58.40 | 2019-2020 | |
| Seqirus USA INC | $57.86 | 2021-2025 | Flucelvax |
| Phadia US INC. | $48.73 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $44.53 | 2020-2021 | |
| Pfizer INC. | $42.97 | 2023-2025 | |
| Abbvie INC. | $39.02 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $31.73 | 2025 | |
| Kaleo, INC. | $27.42 | 2019 | |
| Adlon Therapeutics L.P. | $27.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2019 | |
| Organon LLC | $21.48 | 2023 | Nexplanon |
| Sun Pharmaceutical Industries INC. | $18.44 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.52 | 2019 | |
| Qiagen, LLC | $13.81 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $13.50 | 2025 | Neffy |
| Genentech USA, INC. | $13.30 | 2020 | |
| Corium, LLC | $12.34 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $7.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.